VEGFA and Hypertension: A recent meta‐analysis found that co‐administered ICI with anti‐VEGF agents can increase the risk of a grade 3–4 hypertension, a grade 3–4 cardiac disorder, an all‐grade cardiac disorder, a grade 3–4 arterial thromboembolic event, an all‐grade arterial thromboembolic event, and a grade 3–4 venous thrombotic event compared to anti‐VEGF agents alone.